Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase
- 28 February 2011
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 161 (2), 224-232
- https://doi.org/10.1016/j.ahj.2010.10.023
Abstract
Hospitalization for acute heart failure syndromes (AHFS) predicts a poor prognosis, with postdischarge mortality and rehospitalization rates reaching 45% within 60 to 90 days. Despite the use of evidence-based therapies and adherence to national process measures, these event rates have largely remained the same over the past decade. Given the current and growing burden of AHFS, there exists a substantial unmet need for novel therapies that improve outcomes. However, attempts to improve symptoms and/or reduce postdischarge events have failed to produce positive results, either because of safety and/or efficacy. These negative results may be related to the drug itself, the protocol in terms of patient selection and/or end points, and/or the trial execution. Although experts may not agree on the exact reasons to explain the lack of success to date of phase III trials in AHFS, there is agreement that clinical benefits observed in phase II trials were not reproduced in phase III trials. A different approach may be needed. In November of 2009, a meeting was held at the Food and Drug Administration with the primary purpose of identifying the reasons why benefits observed during phase II did not translate into benefits in phase III to improve future trial design. Although multiple domains of trial design were discussed, the participants identified a lack of in-depth understanding of novel molecules before pivotal trials in AHFS as a possible contributor to the disappointing results of recent large trials. In this brief report, we outline the T1 or translational phase of research for AHFS clinical development as an important first step toward greater success in AHFS clinical trials.Keywords
This publication has 43 references indexed in Scilit:
- Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart FailureNew England Journal of Medicine, 2010
- Early follow-up after hospitalization for heart failureNature Reviews Cardiology, 2010
- Trends in Length of Stay and Short-term Outcomes Among Medicare Patients Hospitalized for Heart Failure, 1993-2006JAMA, 2010
- Rehospitalizations among Patients in the Medicare Fee-for-Service ProgramNew England Journal of Medicine, 2009
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- The Meaning of Translational Research and Why It MattersJAMA, 2008
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Study on the Effect of Oral Tolvaptan on Left Ventricular Dilation and Function in Patients With Heart Failure and Systolic DysfunctionJournal of the American College of Cardiology, 2007
- Tezosentan in patients with acuteheart failure and acute coronary syndromesJournal of the American College of Cardiology, 2003
- RITZ-5: randomized intravenousTeZosentan (an endothelin-A/B antagonist)for the treatment of pulmonary edemaJournal of the American College of Cardiology, 2003
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002